Huntington's disease (HD) is a progressive neurodegenerative disorder that affects motor, cognitive, and behavioral functions, where accurate characterization of disease progression remains essential to improve patient outcome and quality of life. Unsupervised machine learning (ML) approaches have demonstrated the ability to uncover disease progression trajectories and meaningful latent stages from longitudinal data; however, their limited interpretability restricts clinical trust and translation. We extend a previously proposed ML-based disease staging framework by applying an explainability analysis to the extracted feature representations and discovered disease stages. Applied to the Enroll-HD dataset, we first project the learned representations into a lower-dimensional space to intuitively assess whether the resulting clusters align with the progression of established clinical measures. We then use saliency maps to identify the clinical features that most strongly contribute to the learned embeddings over time. Finally, we train a surrogate classifier and apply SHAP to quantify feature importance for cluster assignments and to analyze which clinical variables drive transitions between disease stages. The explainability analysis indicates that the learned embeddings capture clinically meaningful disease structure, aligning with established motor and functional severity scores and exhibiting progressive deterioration across clusters. Within this analysis, SHAP reveals a stratification of disease stages, ranging from early cognitive-motor impairment to severe functional dependency, consistent with known clinical progression patterns, while also highlighting intra-stage variability.
Huntington's disease (HD) is a progressive brain disorder that gradually affects movement, cognitive function, and behavior. Identifying the stage of the disease accurately and consistently is important for understanding its course, grouping patients, personalized care, and discovering treatment. Existing clinical staging frameworks rely primarily on predefined clinical measurement thresholds and clinical expert decisions, yet these discrete cut-offs may obscure meaningful intra-stage variability and remain vulnerable to inter-rater differences, especially in motor and functional assessments. To address these limitations, we developed an unsupervised machine learning framework based on dynamic graph representation learning to capture temporal relationships within and across patients from longitudinal clinical measurements. Using the learned representations, we applied K-means++ clustering to identify well-separated groups. We then iteratively increased the number of clusters (k), using stability analysis to assess robustness and reveal additional meaningful clusters beyond the initial optimal solution. We applied the framework to 302 individuals from the Enroll-HD cohort (1,477 visits, 44 clinical variables per visit; 80% manifest participants), enabling data-driven discovery of HD stages reflecting natural clinical progression. Despite the limited cohort size, the proposed framework achieved robust clustering performance using a four-dimensional latent space, identifying four meaningful and statistically distinct disease stages through clustering stability analysis. Each stage corresponded to well-defined clinical measurement boundaries, with minimal overlap compared to previously established clinical staging methods.
Lubna M. Abu Zohair, Marta Vallejo, MD Azher Uddin +2
Parkinson's disease (PD) is a progressive disorder in which symptom burden and functional impairment evolve over time, making severity staging essential for clinical monitoring and treatment planning. However, many computational studies emphasize binary PD detection and do not fully use repeated follow-up clinical assessments for stage-aware prediction. This study proposes STEP-PD, a severity-aware machine learning framework to classify PD severity using clinically interpretable boundaries. It leverages all available visits from the Parkinson's Progression Markers Initiative (PPMI) and integrates routinely collected subjective questionnaires and objective clinician-assessed measures. Disease severity is defined using Hoehn and Yahr staging and grouped into three clinically meaningful categories: Healthy, Mild PD (stages 1-2), and Moderate-to-Severe PD (stages 3-5). Three binary classification problems and a three-class severity task were evaluated using stratified cross-validation with imbalance-aware training. To enhance interpretability, SHAP was used to provide global explanations and local patient-level waterfall explanations. Across all tasks, XGBoost achieved the strongest and most stable performance, with accuracies of 95.48% (Healthy vs. Mild), 99.44% (Healthy vs. Moderate-to-Severe), and 96.78% (Mild vs. Moderate-to-Severe), and 94.14% accuracy with 0.8775 Macro-F1 for three-class severity classification. Explainability results highlight a shift from early motor features to progression-related axial and balance impairments. These findings show that multimodal clinical assessments within the PPMI cohort can support accurate and interpretable visit-level PD severity stratification.
Md Mezbahul Islam, John Michael Templeton, Christian Poellabauer +1
Deep learning models for dynamic survival analysis (DSA) achieve strong predictive performance by incorporating longitudinal patient data, but their black box nature limits clinical trust and adoption. Existing explainability methods cannot handle longitudinal, irregular inputs and functional survival outputs simultaneously, which limits their usability in DSA. We propose DynSHAP, a SHAP framework suited specifically for dynamic survival analysis. It extends common marginal SHAP estimators to this setting by treating time--feature pairs as players in the Shapley game. We further introduce Temporal DynSHAP, which learns linear dependencies in features over time and uses conditional sampling to address them in explanations. When applied to synthetic data with known ground-truth attributions, Temporal DynSHAP recovers temporally dependent features more accurately than marginal estimators for a given state-of-the-art model. Applied to two real-world clinical datasets and two DSA architectures, DynSHAP produces attributions faithful to model learning, allowing medical experts to see which patient information drove the prediction and when.